Arbutus Biopharma vs Scholar Rock
Free cash flow was −$40 million at Arbutus Biopharma and −$301 million at Scholar Rock.
Side by side
| Arbutus Biopharma | Scholar Rock | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $14M | $0M |
| Revenue growth | 128.2% | — |
| Revenue growth a year, last 5 years | 15.4% | — |
| Gross margin | — | — |
| Operating margin | −271.0% | — |
| Net margin | −237.9% | — |
| Free cash flow | −$40M | −$301M |
| Free cash flow margin | −281.4% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.2% | 14.9% |
| Last close | $4.09 | $43.20 |
| P/E at the last close | 3.6× | — |
| Insider trades, last 12 months | — | sold $19.4 million |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arbutus BiopharmaScholar Rock
Operating margin
Percent of revenue
Arbutus BiopharmaScholar Rock
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arbutus BiopharmaScholar Rock
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arbutus Biopharma and Scholar Rock pages.